The global primary care PoC diagnostics market size is expected to reach USD 26.08 billion by 2030, according to a new report by Grand View Research, Inc., registering a 2.8% CAGR during the forecast period. Flexible and forward-thinking core molecular labs have been embracing and supporting the use of POC tests to move screening of many common targets to hospital receiving rooms and physicians’ offices.
As per a study conducted by the American Journal of Clinical Pathology in 2014, it was found that POC testing improved clinical operations for manufacturers by reducing follow-up calls and letters of patients by 85.0% and 89.0%, respectively, and reducing their follow-up visits by 61.0%. It was also observed that the number of tests ordered decreased by 21.0%.
Furthermore, rise in the number of tests receiving a waived status under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) is anticipated to aid market growth. Researchers and manufacturers are increasingly recommending these tests owing to cost reduction of about USD 12-15 per patient and reduction in follow up tests by about 50.0%. However, there is a massive overlap between different methods and their areas of usage. For instance, panels to measure glucose and quick international normalized ratio tests were originally meant for self-testing but are now used in hospitals and primary settings instead.
Request a free sample copy or view report summary: Primary Care PoC Diagnostics Market Report
The cancer markers segment is expected to register the fastest CAGR during the forecast period. The rising cancer incidences, increased demand for screening cancer, and technological advancements are driving the segment’s growth.
Increase in out-patient practices for lipid testing as part of a routine checkup is expected to positively enhance the adoption rate of lipid testing in the market, giving it a prominent spot in the overall market by product
In terms of end use, while collaborative research for advanced and more accurate POC testing kits by research institutes and biotech firms is likely to facilitate the physicians’ office segment, government initiatives and projects to extend primary care facilities will boost the non-practice clinics segment
The North America primary care POC diagnostics market is more developed compared to the rest of the world. The regional segment is fueled by availability of several innovative and advanced POC diagnostic products and growing awareness and demand for point-of-care diagnostics in primary home healthcare and assisted healthcare
The U.S. market is witnessing a shift toward increasing patient involvement in home care, home-based tests, and monitoring instruments. In addition, digitalization, EHR, telemedicine, and web-enabled solutions of monitoring data are gaining pace in U.S., thereby driving its growth
Grand View Research has segmented the global primary care POC diagnostics market based on product, end use, and region:
Primary Care PoC Diagnostics Product Outlook: (Revenue, USD Billion, 2018 - 2030)
Glucose Testing
Hb1Ac Testing
Coagulation Testing
Fertility/Pregnancy
Infectious Disease
Cardiac Markers
Thyroid Stimulating Hormone
Hematology
Primary Care Systems
Decentralized Clinical Chemistry
Feces
Lipid Testing
Cancer Marker
Blood Gas/Electrolytes
Ambulatory Chemistry
Drug of Abuse (DOA) Testing
Autoimmune Diseases
Urinalysis/Nephrology
Primary Care PoC Diagnostics End Use Outlook: (Revenue, USD Billion, 2018 - 2030)
Pharmacy & Retail Clinics
Physician Office
Urgent Care Clinics
Non-practice Clinics
Primary Care PoC Diagnostics Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Asia Pacific
China
Japan
India
South Korea
Australia
Latin America
Brazil
Middle East and Africa (MEA)
Saudi Arabia
UAE
South Africa
List of Key Players in Primary Care PoC Diagnostics Market
F Hoffmann-La Roche Ltd.
Danaher
Abbott
Siemens Healthineers
BIOMÉRIEUX
QIAGEN
Nova Biomedical
Johnson & Johnson Services, Inc.
OraSure Technologies, Inc.
BD
"The quality of research they have done for us has been excellent..."